Effect of interferon and ribavirin combination therapy in sixty-two patients with chronic hepatitis C originating from a single blood donor.
10.3760/cma.j.issn.1007-3418.2012.08.010
- Author:
San-du LIU
1
;
Ming-liang CHENG
;
Hong REN
;
Qing-kun YANG
;
De-yun SHU
Author Information
1. Department of Infectious Diseases, the Qiannan People's Hospital in Guizhou Province, Guizhou Qiannan, China.
- Publication Type:Clinical Trial
- MeSH:
Adolescent;
Adult;
Antiviral Agents;
administration & dosage;
adverse effects;
therapeutic use;
Blood Donors;
Child;
Drug Therapy, Combination;
Female;
Follow-Up Studies;
Hepacivirus;
drug effects;
genetics;
Hepatitis C, Chronic;
drug therapy;
virology;
Humans;
Interferon-alpha;
administration & dosage;
adverse effects;
therapeutic use;
Male;
Middle Aged;
RNA, Viral;
blood;
Recombinant Proteins;
administration & dosage;
adverse effects;
therapeutic use;
Ribavirin;
administration & dosage;
adverse effects;
therapeutic use;
Transfusion Reaction;
Treatment Outcome;
Viral Load;
Young Adult
- From:
Chinese Journal of Hepatology
2012;20(8):589-592
- CountryChina
- Language:Chinese
-
Abstract:
To investigate the efficacy of interferon alpha 2 b plus ribavirin combination therapy in sixty-two patients with chronic hepatitis c (CHC) infection originating from a single blood donor. The 62 patients who developed CHC following blood transfusion from a known single infected donor were treated with interferon and ribavirin combination therapy for 48 weeks and followed-up for 96 weeks. The therapy regimen consisted of subcutaneous administration of 3-500 MIU interferon alpha 2 b every other day and daily oral administration of 0.6-1.0 g of ribavirin. Patients were monitored during treatment and in follow-up for sustained virological response (SVR), early virology response (EVR), treatment end virology response (ETVR), biochemical response of withdrawals, and side effects. The SVR rate was 83.9% (52/62). The EVR rate was 95.2% (59/62). The ETVR rate was 87.1% (54/62). The biochemical response rate after withdrawal of treatment was 100.0%. Eight patients developed mildly abnormal thyroid function as a result of the interferon therapy, but all were able to complete the antiviral treatment regimen under the care of endocrinologists. Younger age, relatively short course of disease, low viral load, and better compliance, but not sex, were correlated to curative effect of the combination therapy. Interferon alpha 2 b plus ribavirin combination therapy had a significant curative effect on a group of 62 CHC patients originating from a single case, with 52 of the patients showing SVR out to 96 weeks after therapy. Antiviral treatment is recommended for hepatitis C virus-positive patients to eradicate the virus and prevent disease progression.
